Key Insights

Highlights

Treatment Research

1 treatments under study, led by Incobotulinumtoxina

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

100%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 4 (1)

Trial Status

Unknown1

Clinical Trials (1)

Showing 1 of 1 trials
NCT01583478Phase 4Unknown

Comparison of Escalating Doses of IncobotulinumtoxinA (Xeomin®) in the Treatment of Glabellar Rhytids

Showing all 1 trials

Research Network

Common Treatments

  • Incobotulinumtoxina1

Active Sponsors

  • Merz North America, Inc.1
  • The Maas Clinic1

Top Investigators

Related Conditions

  • Skin Aging1

Activity Timeline